Evolving Standards in Biologics Development: What’s New in PDA TR 56 (2026) on Level of GMPs Needed and Why It Matters for Startups

As a CMC and quality expert with over two decades in the biopharma industry, I’ve had countless conversations with leaders at small biotech companies and startups navigating their first asset. One topic that comes up repeatedly? The misconception that material for the initial Investigational New Drug (IND) filing doesn’t need to follow Good Manufacturing Practices (GMP). Let me be clear: all material administered to humans must be produced under GMP. The key is understanding that GMP isn’t a binary switch—it’s a graded approach that ramps up in rigor as you progress toward commercialization. This “phase-appropriate” mindset is crucial for avoiding costly delays, regulatory hurdles, and compliance pitfalls.

That’s why the recent release of the Parenteral Drug Association’s (PDA) Technical Report No. 56 (Revised 2026): Application of Phase-Appropriate Quality Systems and Good Manufacturing Practice to the Development of Biological Product Drug Substance is such a gamechanger. Building on the original 2012 version and the 2016 update, this significantly expanded edition (now at 63 pages, up from 36) aligns with the latest regulations, guidances, and modern quality thinking. If you’re at a startup or managing your first asset, this report could be your roadmap to smarter, more efficient development. Let’s break down the key changes, their benefits, and the real-world impact for smaller players.

Key Changes from the 2016 Edition
The 2016 revision was already a solid foundation, emphasizing how GMP requirements evolve from discovery/R&D through Phase 3 trials and commercial launch. It introduced a framework tailored for non-commercial sites like universities or early-stage firms, focusing on risk-based decisions and knowledge management under ICH Q8-Q11 guidelines.

The 2026 revision takes this further by:
– Expanding Coverage on Risk Mitigation**: It provides detailed advice on reducing risks of delays, failures, and GMP noncompliance during critical stages like product development, analytical method development, and scale-up from Phase 1 to Phase 3, including validation. This includes best practices to implement *before* full GMP manufacturing kicks in—think proactive strategies for cell line development, process characterization, and supply chain robustness.

Alignment with Modern Regulations and Guidances**: Updated to reflect post-2016 advancements, such as enhanced ICH Q12 (lifecycle management) integration, FDA’s evolving expectations on digital tools for quality systems, and EU Annex 1 revisions on sterile manufacturing. It incorporates lessons from the COVID-19 era, like accelerated pathways and remote audits, making it more relevant to today’s fast-paced environment.

– Deeper Dive into Best Practices: New sections emphasize continual improvement, data integrity in early phases, and integration of quality risk management (QRM) with knowledge management. For example, it offers more granular guidance on control strategies for biological variability, which wasn’t as fleshed out in 2016.
– Broader Scope for Biologicals: While still focused on therapeutic proteins, it now better addresses emerging modalities like gene therapies and cell-based products, with updated recommendations on substrate development and testing (e.g., mammalian vs. microbial systems).

These updates stem from consensus among industry experts, regulators, and academics, ensuring the report isn’t just theoretical—it’s practical and actionable.

Benefits of These Changes

The revisions aren’t just incremental; they’re transformative, especially in a landscape where regulatory scrutiny is intensifying while innovation timelines are shrinking.

1. Risk Reduction and Efficiency: By outlining “what must be done” versus “nice-to-haves,” the report helps teams prioritize resources. For instance, it clarifies how to apply QRM early to avoid over-engineering Phase 1 processes, potentially saving months and millions in development costs. In my experience, startups often underestimate scale-up risks—this guidance can prevent common traps like inadequate process validation leading to IND holds.
2. 2. Compliance Without Overburden: The graded approach demystifies GMP escalation. Early phases focus on basic controls (e.g., documentation, training), ramping up to full validation by Phase 3. This flexibility means you don’t need a commercial-level quality system from day one, but you build toward it seamlessly, aligning with FDA’s “cGMP for Phase 1” guidance.3. Knowledge Building for Long-Term Success: Enhanced emphasis on lifecycle management encourages capturing data from the start, turning early experiments into a foundation for BLA submissions. This modern quality thinking—rooted in ICH Q10—promotes proactive issue resolution, reducing surprises during tech transfer or audits.Overall, these changes foster a more innovative, risk-aware culture, enabling faster time-to-clinic without compromising safety or quality.
3. Impact on Startups and First-Asset Companies
   For smaller companies, where resources are lean and every decision counts, TR 56 (2026) is particularly empowering. In my consulting work, I’ve seen firsthand how first-asset teams struggle with balancing speed and compliance—often assuming “lab-grade” material suffices for preclinical or early clinical use. Wrong. As the report reinforces, GMP applies from the first human dose, but in degrees: basic traceability in tox studies evolves to robust controls by pivotal trials.- Cost Savings and Investor Appeal: By adopting phase-appropriate practices, startups can avoid rework. For example, implementing early QRM might catch a cell bank issue before it derails a Phase 2 trial, preserving funding runway. Investors love this: it signals disciplined development, increasing valuation and partnership potential.- Regulatory Navigation: Smaller firms often lack in-house regulatory expertise. The updated report’s alignment with current FDA/EU guidances provides a “cheat sheet” for IND/IMPD filings, reducing rejection risks. It’s especially helpful for university spinouts or grant-funded projects, where commercial manufacturing isn’t the immediate goal.
4. – Scalability for Growth: As your first asset advances, the guidance helps transition to partners or CMOs smoothly. I’ve advised companies where ignoring early GMP led to painful tech transfers— this report equips you to build scalable systems from the outset.In frequent discussions with smaller biotechs, I emphasize: Don’t wait for Phase 3 to “get serious” about quality. Start phase-appropriate, and you’ll accelerate your path to patients while mitigating risks.If you’re in biologics development, get a copy of TR 56 (2026) from the PDA —it’s a worthwhile investment. Have thoughts on phase-appropriate GMP or experiences with first assets? Drop a comment below; I’d love to connect and discuss! Our teams can also help you accelerate your programs to commercial approval.